ARMP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide...

Stats
Dagens volum	6 133.00
Gjennomsnittsvolum	15 935.00
Markedsverdi	90.01M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $-0.310 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.300
ATR14	$0.0460 (1.77%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Patti Joseph M	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Patti Joseph M	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Peterson Todd C.	Buy	54 343	Stock Options (Right to Buy)

INSIDER POWER
98.47
Last 92 transactions
Buy: 43 961 909 \| Sell: 1 182 185

Armata Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Armata Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$4.53M
Bruttogevinst:	$3.56M (78.54 %)
EPS:	$-1.910

FY	2023
Omsetning:	$4.53M
Bruttogevinst:	$3.56M (78.54 %)
EPS:	$-1.910

FY	2022
Omsetning:	$5.51M
Bruttogevinst:	$4.62M (83.81 %)
EPS:	$-1.080

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.960

Financial Reports:

No articles found.

Armata Pharmaceuticals

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.